Photodynamic Therapy for Subfoveal Choroidal Neovascularisation in Various Diseases among which Age-related Macular Degeneration: An Update
| Autor: | Hubert van den Bergh, Jean-Pierre Ballini, Michel Sickenberg |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Visual acuity genetic structures business.industry medicine.medical_treatment Subgroup analysis Photodynamic therapy Dermatology Macular degeneration medicine.disease Verteporfin eye diseases Clinical trial Ophthalmology Age related medicine Surgery Functional ability medicine.symptom business medicine.drug |
| Zdroj: | Medical Laser Application. 18:65-78 |
| ISSN: | 1615-1615 |
| DOI: | 10.1078/1615-1615-00089 |
| Popis: | Summary Photodynamic therapy (PDT) with Verteporfin represents a major advance in the treatment of subfoveal choroidal neovascularisation (CNV). Patients presenting this disease tend to lose about 2 lines of visual acuity in the first 3–6 months after PDT, after which vision can be stabilised for at least 4 years. Contrast sensitivity loss secondary to subfoveal CNV is also strongly reduced by PDT. The latter is essential to the quality of life and functional ability, especially in low vision patients. In addition PDT of subfoveal CNV was shown to be quite safe. Some of the recent data obtained in the Visudyne clinical trials are summarised with an emphasis on subgroup analysis. The observed initial loss in visual acuity, the necessity for repetitive treatment and the inherent relatively high cost of the procedure, as well as the lack of response in some subgroups of patients, has led to the search for improvements on the initial procedure. In this paper we present some of the approaches taken. Finally, the selectivity issues central to PDT of subfoveal CNV are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect